This product is supplied strictly for laboratory and research purposes only
Blocking NNMT activity has been shown in research settings to influence body composition, leading to reduced adipocyte size, alterations in fat mass, and measurable changes in plasma biomarkers such as glucose and cholesterol
However, side effects can still occur
Confirmed at 28 days A follow-up 28-day study (Babula et al., 2024) extended the finding: 5-Amino-1MQ dose-dependently limited body weight and fat mass gain without changing food intake, and it improved liver markers in obese mice
Why it matters for body composition: By decreasing chronic inflammation and improving how the body handles glucose, Amlexanox creates a more favorable internal environment for fat loss and muscle gain
Most current research-context subcutaneous protocols cite 300-500 mcg/day, but no published human pharmacokinetic study has formally evaluated the subcutaneous route